- Subject Team
Jiang Jieling
M.D., Ph.D., Associate Chief Physician
Diagnosis and treatment of various hematological disorders, including anemia, thrombocytopenia, acute and chronic leukemia, lymphoma and multiple myeloma, especially allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.
Department of Hematology
Profile
Education & Training
08/2012-01/2010 Visiting Scholar
Department of cellular therapy/adult bone marrow transplantation, Duke University Medical Center, Durham, NC.The United States
08/1998-07/2000 M.D., Ph.D.
Academy of Medical Science, Peking Union Medical College Hospital, Beijing, China
08/1994-07/1998 Bachelor And Master degree in Medicine
Harbin Medical University, Harbin, Heilongjiang, China
09/1992-07/1994 Basic Training Before Medical Study
Department of Biology, Nankai University, Tianjin, China
08/2012-01/2010 Visiting Scholar
Department of cellular therapy/adult bone marrow transplantation, Duke University Medical Center, Durham, NC.The United States
08/1998-07/2000 M.D., Ph.D.
Academy of Medical Science, Peking Union Medical College Hospital, Beijing, China
08/1994-07/1998 Bachelor And Master degree in Medicine
Harbin Medical University, Harbin, Heilongjiang, China
09/1992-07/1994 Basic Training Before Medical Study
Department of Biology, Nankai University, Tianjin, China
Work Experiences:
07/2000--present Department of Hematolgy, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
07/2000--present Department of Hematolgy, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China
Honors and Awards
2016 “Le Wen Zhao” Award nomination for Excellence in Clinical work,
Shanghai General Hospital
2007 Outstanding Staff, Shanghai General Hospital
2016 “Le Wen Zhao” Award nomination for Excellence in Clinical work,
Shanghai General Hospital
2007 Outstanding Staff, Shanghai General Hospital
Selected Publications
1.Jiang J, Wang C. Allogeneic Stem Cell Transplantation Following Reduced-intensity Conditioning Regimen as Salvage Therapy for Refractory Leukemia.（in Chinese, Editorial）Journal of Leukemia and Lymphoma, 2009,18(2):65-68
2.Jiang J, Wang C, Yan S, et al. Allogeneic Stem Cell Transplantation Following Reduced-intensity Conditioning Regimen in the Treatment of Relapsed and Refractory Leukemia.（in Chinese）Chinese Journal of Hematology, 2008,29(8):517-521
3.Jiang J, Wang C, Yan S, et al. Allogeneic Stem Cell Transplantation Following Reduced-intensity Conditioning Regimen in the Treatment of Relapsed and Refractory Leukemia(in English). The 50th conference of American society of hematology, Abstract #4425
4.Yang J, Jiang J, Wang C, et al. Early Use of anti-CD25 monoclone Antibody for the treatment of glucocorticosteroid resistant GVHD. Chinese Journal of Organ Transplantation, 2008,29(9):565-567
1.Jiang J, Wang C. Allogeneic Stem Cell Transplantation Following Reduced-intensity Conditioning Regimen as Salvage Therapy for Refractory Leukemia.（in Chinese, Editorial）Journal of Leukemia and Lymphoma, 2009,18(2):65-68
2.Jiang J, Wang C, Yan S, et al. Allogeneic Stem Cell Transplantation Following Reduced-intensity Conditioning Regimen in the Treatment of Relapsed and Refractory Leukemia.（in Chinese）Chinese Journal of Hematology, 2008,29(8):517-521
3.Jiang J, Wang C, Yan S, et al. Allogeneic Stem Cell Transplantation Following Reduced-intensity Conditioning Regimen in the Treatment of Relapsed and Refractory Leukemia(in English). The 50th conference of American society of hematology, Abstract #4425
4.Yang J, Jiang J, Wang C, et al. Early Use of anti-CD25 monoclone Antibody for the treatment of glucocorticosteroid resistant GVHD. Chinese Journal of Organ Transplantation, 2008,29(9):565-567